MedTrace Logo

Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency

NCT04138251 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-10-28

No results posted yet for this study

Summary

Treatment of neutropenia of G6PC3 and Glycogenosis type 1b patients with empagliflozin

Conditions

  • Glycogen Storage Disease Type I
  • Glucose 6 Phosphatase Deficiency

Interventions

DRUG

Empagliflozin

oral administration of Empagliflozin

Sponsors & Collaborators

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • Xavier Stephenne, MD, PhD · Cliniques universitaires St Luc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-20
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04138251 on ClinicalTrials.gov